Fredag 30 Oktober | 10:54:20 Europe / Stockholm
Est. tid*
2027-05-20 N/A Årsstämma
2027-02-17 08:55 Bokslutskommuniké 2026
2026-11-11 08:00 Kvartalsrapport 2026-Q3
2026-08-19 - Kvartalsrapport 2026-Q2
2026-05-22 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2026-05-21 - Årsstämma
2026-05-13 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2026-01-19 - Extra Bolagsstämma 2026
2025-11-20 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning CINPHA 0.00 SEK
2025-05-22 - Årsstämma
2025-05-20 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm, Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Number of shares and votes in Cinclus Pharma

2026-10-30 09:00:00

The number of shares and votes in Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) has changed as a result of the issue and repurchase of 1,000,000 class C shares in accordance with the Board of Directors’ resolution announced on 7 October 2026 and registered with the Swedish Companies Registration Office on 8 October 2026.

As of 30 October 2026, the last trading day of the month, the total number of shares in Cinclus Pharma amounts to 48,392,219, of which 46,537,789 are ordinary shares and 1,854,430 are class C shares. The total number of votes amounts to 46,723,232, of which the ordinary shares correspond to 46,537,789 votes and the class C shares correspond to 185,443 votes. The company's share capital has increased through the issue by approximately SEK 19,413, from approximately SEK 920,039 to approximately SEK 939,452.

 

Ordinary shares entitle the holder to one vote per share, while class C shares entitle the holder to 1/10 vote. The class C shares will be held by the company to be used in the future for its long-term share-based incentive programs.